Our Laboratory Implementation Team helps with initial lab setup and implementation, ensuring you have enough space for lab equipment, verifying hazard protocols, validating and testing equipment and more. This team can help set up single pieces of lab equipment or help build an entire new lab. Email us today to get started.
Following the January 2018 FDA reclassification of rapid influenza antigen tests (RIDTs), flu testing technology continues to evolve. While you may still use non-compliant flu tests through their expiration dates, now is the perfect time to explore your options for compliant flu testing.
Contact us to learn more about these featured products and others.Contact Us
Shop Flu Testing Readers
Minimizes visual subjectivity • Similar cost as visually read rapids • Increases accuracy of results
Featured Molecular Flu Test System
Cepheid GeneXpert® IV System
- CLIA waived: flu, strep & flu/RSV combo
- Confirmatory negative or positive Strep A
- 3-step workflow; 2 minutes or less hands-on time
- Walkaway PCR technnology
Shop Molecular Flu Testing*
Amplification technology increases specimen sample quality • Produces extremely accurate and, in some cases, definitive test results
Featured Flu Test Kit
McKesson Consult Influenza A & B
- CLIA waived
- Rapid qualitative test that detects influenza type A and type B antigens directly from nasal swab, nasopharyngeal swab and nasal aspirate/wash specimens
- Results in under 15 minutes
More Products, More Choice
For a complete list of products which meet the new FDA requirements or to schedule a product demonstration, contact your Account Executive.
FDA Flu Reclassification
Effective January 2018, the Food and Drug Administration (FDA) has reclassified rapid influenza antigen detection tests. Here’s what you need to know about this reclassification.
Want to learn more about our product options for flu testing? Let us know!
*Molecular products may only be sold in certain markets. Other restrictions may apply. Contact us to learn more.